T-CELLS COMPRISING TWO DIFFERENT CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF

The present invention provides T-cells modified to express at least two chimeric antigen receptors, wherein one of the CARs binds specifically to an antigen selected from CD138, HER2 and CD24 and another CAR binds specifically a different antigen selected from CD138, HER2 and CD24. Further, the inve...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	LASKOV, Ido, ESHHAR, Zelig, GRISARU, Dan, WAKS, Tova, DESHET-UNGER, Naamit, RAWET SLOBODKIN, Moran, KATZ, Ben Zion, GLOBERSON LEVIN, Anat
Format:	Patent
Sprache:	eng ; fre
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The present invention provides T-cells modified to express at least two chimeric antigen receptors, wherein one of the CARs binds specifically to an antigen selected from CD138, HER2 and CD24 and another CAR binds specifically a different antigen selected from CD138, HER2 and CD24. Further, the invention provides pharmaceutical compositions comprising these CAR T-cells and their use in treatment of cancer, in particular, ovarian cancer, DNA constructs encoding said CARs and methods for preparation of T-cells expressing said CARs. La présente invention concerne des lymphocytes T modifiés pour exprimer au moins deux récepteurs antigéniques chimériques, l'un des CAR se liant de manière spécifique à un antigène choisi parmi CD138, HER2 et CD24 et un autre CAR se liant de manière spécifique à un antigène différent choisi parmi CD138, HER2 et CD24. En outre, l'invention concerne des compositions pharmaceutiques comprenant ces lymphocytes T à CAR et leur utilisation dans le traitement du cancer, en particulier du cancer de l'ovaire, des constructions d'ADN codant pour lesdits CAR et des procédés de préparation de lymphocytes T exprimant lesdits CAR.